ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidance

Subcategories:EthicsLegal UpdatesLegislation & AdvocacyResearch Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

 

Lightspring/shutterstock.com

The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

Dana Direnzo, MD, Ami A. Shah, MD, MHS, Clifton O. Bingham III, MD, & Laura C. Cappelli, MD, MHS  |  May 17, 2017

A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

Active Advocacy in the Sunshine State: Florida Society Presses for Legislative Changes to Protect Patient Access to Medications

Susan Bernstein  |  May 17, 2017

At their state capitol in Tallahassee on March 28, seven board members of the Florida Society of Rheumatology (FSR) lobbied to support legislation regarding prior authorization, step therapy and non-medical switching. They also educated lawmakers about rheumatic diseases and how access to the right therapy may dramatically improve patients’ lives. “We talked about the problems encountered…

Alliance Working to Rein in Power of PBMs

Kathy Holliman  |  May 17, 2017

A coalition of patient and provider groups, including the ACR, is raising awareness about the effect of pharmacy benefit managers (PBMs) on patient care and the cost of prescription drugs. The Alliance for Transparent and Affordable Prescriptions, or ATAP, argues that too few restrictions have been placed on PBM transparency, and requirements for PBMs to…

Advocating for CMMI Reform, Looking Ahead to Alternative Payment Models

Carina Stanton  |  May 17, 2017

The work of health policy reform is a marathon, not a sprint. The ACR is encouraged by the forward progress being made in collaboration with the American Medical Association and other physician-led organizations within the Healthcare Leaders for Accountable Innovation in Medicare and Medicaid coalition (known as the AIM coalition) to advocate for physicians’ ability…

Experimental Drug Combination Curbs Chikungunya Arthritis in Mice

Bryn Nelson, PhD  |  May 16, 2017

Doctors have had few options to treat the chronic rheumatoid arthritis-like symptoms associated with chikungunya virus infections beyond over-the-counter pain relievers. A recent study in Science Translational Medicine has spurred new optimism by finding that a combination therapy—the anti-rheumatic drug abatacept paired with a chikungunya-neutralizing monoclonal antibody—abolished acute symptoms in infected mice.1 The strategy must…

Fellows’ Forum: Why Rheumatology Fellows Should Get Involved with Advocacy

Alexandra Perel-Winkler, MD, & Christopher A. Mecoli, MD  |  May 16, 2017

Introduction Interest in rheumatology continues to grow, with more than 240 new adult and pediatric fellows to begin their training in the coming academic year. Given the broad and diverse career opportunities, it is an ACR goal to help guide trainees in their career decisions and professional development. Rheumatology fellowship often marks the transition from…

Rheumatology Research Foundation Offers Innovative Research Award for Community Practitioners

From the College  |  May 16, 2017

The Rheumatology Research Foundation is now offering the Innovative Research Award for Community Practitioners; tailored for physicians interested in disease investigation, it supports research ideas specific to clinical practice. The distinct perspective of clinical rheumatologists opens a window of opportunity for disease investigation that merits support for novel research. With the increasing prevalence of rheumatic…

Aetna CEO Urges Debate on What ‘Single-Payer’ Healthcare Would Be

Reuters Staff  |  May 15, 2017

NEW YORK (Reuters)—Aetna Inc, Chief Executive Officer Mark Bertolini wants a debate about what a single-payer healthcare system in the U.S would look like, but says he does not think the federal government should run it. “I think government-run healthcare would be a bad idea,” Bertolini says during an investor conference on Frida. The government’s…

Lifetime Risk of Hand Arthritis May Be More Than 40%

Madeline Kennedy  |  May 12, 2017

(Reuters Health)—A new study finds that as many as four in 10 people may develop hand osteoarthritis. Among women, researchers found the lifetime risk was 47% while for men it was about 25%. Obese people also had 11% higher lifetime risk than those who were not obese. Hand osteoarthritis can cause disability and problems with…

Johnson & Johnson Discloses U.S. Probe Related to Arthritis Drugs

Reuters Staff  |  May 12, 2017

(Reuters) – Healthcare conglomerate Johnson & Johnson said on Monday the U.S. Department of Justice (DOJ) has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs. The U.S. healthcare company said its Janssen Biotech Inc. unit received a civil investigative demand from the DOJ…

  • « Previous Page
  • 1
  • …
  • 122
  • 123
  • 124
  • 125
  • 126
  • …
  • 249
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences